Domenica Lorusso, ASCO 2022: Trabectedin for the treatment of recurrent ovarian, primary peritoneal, or fallopian tube cancers – Phase 3 MITO23 trial results
The phase 3 MITO23 trial investigated trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients Dr Domenica Lorusso (Fondazione IRCCS National Cancer institute of Milan, Milan, Italy) discusses the rationale for the trial, trabectedin’s mode of action, the phase 3 results, and future planned studies.
The abstract entitled ‘Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23)‘ (Abstract #LBA5504) was presented at the ASCO annual meeting, 3-7 June 2022.
Disclosures: Domenica Lorusso discloses consultancy honoraria from AstraZeneca, Clovis Oncology, GSK, MSD, Immunogen, Genmab, Amgen, Seagen and PharmaMar. She has has been an invited member of advisory boards at Merck Serono, Seagen, Immunogen, Genmab, Oncoinvest, Corcept and Sutro, and an invited speaker and member of the advisory board for AstraZeneca. She receives direct research institutional funding from Clovis Oncology, GSK, MSD and PharmaMar, and grants for traveling from Roche, PharmaMar, AstraZeneca, Clovis Oncology and GSK.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Gynaecological Cancers
Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results – Chemotherapy with tegafur-uracil for locally advanced cervical cancer
Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for […]
Keiichi Fujiwara, ESMO 2022: Clinical trial highlights in gynaecological cancer
Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study. Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!